全球各国每百万人口干预性临床试验注册数量
该研究利用世界卫生组织国际临床试验注册平台(ICTRP)数据,分析1999至2022年全球干预性临床试验注册情况。共分析229个国家和地区注册的910804项试验。结果显示,2009至2022年每百万人口注册试验数全球平均约97项,丹麦、爱沙尼亚、比利时、荷兰和新西兰居前。
要点
- 2009至2022年全球每百万人口注册干预性临床试验约97项。
- 人口超百万的国家中,丹麦、爱沙尼亚、比利时、荷兰和新西兰注册率居前。
- 自1999年以来全球干预性临床试验注册量持续增长,领先国家尤为明显。
核心结论
- 自1999年以来全球干预性临床试验注册量增长,领先国家尤为明显;2009至2022年全球平均约每百万人口97项注册试验;较小的西方国家在每百万人口干预性临床试验注册数上领先。
研究设计与样本
- 从世界卫生组织国际临床试验注册平台(ICTRP)提取1999至2022年逐年注册的干预性临床试验数量,数据截至2024年3月1日,使用Microsoft Excel分析。
- 以国家百万人口数除以其注册试验总数计算每百万人口注册活动,人口数据来自世界银行、中央情报局世界概况和法国国家统计与经济研究所(2022年)。
- 分析两个时段:2009至2022年(注册较完整)和1999至2022年全时段(缓慢追赶)。
主要发现
- 2022年2月ICTRP按国家注册的干预性临床试验共943113项,排除32309项原产国未知的试验后,分析229个国家和地区注册的910804项试验。
- 人口超百万的国家或地区中,2009至2022年每百万人口干预性临床试验注册数前五为丹麦、爱沙尼亚、比利时、荷兰和新西兰;1999至2022年全时段前五为丹麦、爱沙尼亚、比利时、荷兰和拉脱维亚。
- 不论人口规模,两个时段注册数前五的国家或地区均为皮特凯恩、梵蒂冈、托克劳、纽埃和丹麦。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sweden and Denmark are amongst the countries which led the world in clinical trial publications per million population. We need, however, to also assess clinical research activities through trial registration rather than publication alone. Enforceable policies for trial registration before launch facilitated global and national clinical research assessments. The World Health Organisation (WHO) hosts the International Clinical Trials Registry Platform (ICTRP) for interventional clinical trials, with data from the year 1999 and onwards. AIMS: To identify the number of interventional clinical trials registered per million population per country worldwide during the 2009- to 2022-year period, and to examine whether registration activity increased in those years when international registration requirements became more widely adopted as compared to the 1999- to 2022-year period. METHODS: We used the WHO ICTRP to extract the yearly numbers of registered interventional clinical trials. We entered the data in Microsoft Excel. We analysed the two periods of years: from 2009 to 2022 with more complete registration of trials and from the whole period 1999 to 2022 with a slow catch-up. To obtain the trial registration activity by country, we divided the total number of interventional clinical trials registered by the country's population in millions. Information on population numbers originated from the World Bank, the Central Intelligence Agency World Factbook, and The National Institute of Statistics and Economic Studies (of France) as of 2022. We collected data as of 03-01-2024. RESULTS: In February 2022, there were 943,113 interventional clinical trials registered by country on the ICTRP. After excluding 32,309 trials with unknown country of origin, we analysed 910,804 trials registered in 229 countries and territories. For countries or territories with populations over 1 million, the top five in interventional clinical trial registrations per million population during the 2009- to 2022-year period were Denmark, Estonia, Belgium, The Netherlands, and New Zealand. For the 1999- to 2022-year period, these were Denmark, Estonia, Belgium, The Netherlands, and Latvia. The top five countries or territories, irrespective of population, for both periods were Pitcairn, The Vatican, Tokelau, Niue, and Denmark. CONCLUSIONS: Since 1999, there has been worldwide growth in interventional clinical trial registrations, especially amongst top-contributing countries. The global average stands at approximately 97 registered trials per million people from 2009 to 2022, highlighting the need for continued efforts to improve trial registration and production. Smaller Western countries lead in interventional clinical trials per million population.
引用
- Bjerg JL, Nikolova D, Gluud C, et al. Interventional clinical trials registered per million population per country worldwide. Trials. 2025. PMID: 41291769. doi:10.1186/s13063-025-09185-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。